A detailed history of China Universal Asset Management Co., Ltd. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 49,238 shares of LYEL stock, worth $30,035. This represents 0.01% of its overall portfolio holdings.

Number of Shares
49,238
Previous 29,951 64.4%
Holding current value
$30,035
Previous $43,000 55.81%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$1.13 - $1.88 $21,794 - $36,259
19,287 Added 64.4%
49,238 $67,000
Q2 2024

Jul 19, 2024

SELL
$1.3 - $3.01 $24,575 - $56,901
-18,904 Reduced 38.69%
29,951 $43,000
Q1 2024

Apr 29, 2024

BUY
$1.71 - $3.07 $33,717 - $60,534
19,718 Added 67.67%
48,855 $109,000
Q4 2023

May 21, 2024

SELL
$1.39 - $2.35 $27,408 - $46,337
-19,718 Reduced 40.36%
29,137 $56,000
Q4 2023

Jan 23, 2024

BUY
$1.39 - $2.35 $31,554 - $53,347
22,701 Added 352.72%
29,137 $57,000
Q3 2023

May 21, 2024

BUY
$1.45 - $3.35 $4,589 - $10,602
3,165 Added 96.76%
6,436 $9,000
Q3 2023

Oct 30, 2023

BUY
$1.45 - $3.35 $4,589 - $10,602
3,165 Added 96.76%
6,436 $9,000
Q2 2023

May 21, 2024

SELL
$1.89 - $3.86 $209 - $428
-111 Reduced 3.28%
3,271 $10,000
Q2 2023

Jul 27, 2023

SELL
$1.89 - $3.86 $209 - $428
-111 Reduced 3.28%
3,271 $10,000
Q1 2023

May 21, 2024

BUY
$1.97 - $3.58 $1,672 - $3,039
849 Added 33.52%
3,382 $7,000
Q1 2023

Apr 27, 2023

BUY
$1.97 - $3.58 $1,672 - $3,039
849 Added 33.52%
3,382 $8,000
Q4 2022

May 21, 2024

SELL
$2.78 - $8.09 $128,775 - $374,744
-46,322 Reduced 94.82%
2,533 $8,000
Q4 2022

Jan 31, 2023

BUY
$2.78 - $8.09 $589 - $1,715
212 Added 9.13%
2,533 $9,000
Q3 2022

Oct 21, 2022

BUY
$5.54 - $8.27 $12,858 - $19,194
2,321 New
2,321 $17,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.